Kyverna Therapeutics (KYTX)

• Market cap: $480M
• 1 day: -3.19%
• 5 days: 2.2%
• 1 month: -7.61%
• 3 months: -13.2%
• 6 months: -22.95%
• Year to date: -10.03%
• 1 year: 150.48%
• 5 years: -73.7%
• 10 years: -73.7%
• Sector: Healthcare
• Industry: Biotechnology

About: Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Employees: 129